Novo Nordisk, the company behind semaglutide (Ozempic, Wegovy), is developing a next-generation oral medication called amycretin that combines two distinct hormonal mechanisms in a single pill. Early trial data suggests it may achieve weight loss results that surpass even injectable semaglutide. What Is Amycretin? Amycretin is an oral co-agonist that simultaneously activates two receptors: the…
English 
Urdu